Radiation Oncology

Journal Club ft. NEJM publications

Questions discussed in this category

In light of the improved outcomes seen in patients receiving IO +/- olaparib, what role, if any, do you think pelvic radiation still plays in the management of patients with advanced endometrial cancer?

3 Answers available

Are you routinely using neoadjuvant cemiplimab for cutaneous squamous cell carcinoma of any site?

Majority of patients on the seminal trial (Gross et al., PMID 36094839) had tumors isolated to head & neck, what was the rationale for this?

4 Answers available

Would you continue cemiplimab or pembrolizumab adjuvantly, following resection of initially unresectable cutaneous squamous cell carcinoma?

Do you base your decision on extent of residual disease? Does the use of (neo)adjuvant immunotherapy have an impact on surgical site size or he...

4 Answers available

Is the phase 2 data regarding neoadjuvant cemiplimab in cutaneous squamous cell carcinoma sufficient to adopt for all patients or will you await phase 3 data?

Is a placebo-controlled trial anticipated?

6 Answers available

Do you consider downstaging neoadjuvant cemiplimab for borderline resectable CSCC in order to facilitate surgical resection?

3 Answers available

What is your approach to patients with unresectable, node-negative perihilar cholangiocarcinoma who have undergone biliary stenting and have no evidence of distant disease?

If borderline resectable, can the TOPAZ regimen be considered for downstaging effects?

4 Answers available

Can adjuvant nivolumab for bladder CA as per Checkmate 274 be extrapolated for the concurrent chemoRT bladder preservation setting?

4 Answers available

Can the results of Checkmate 577 be applied to patients who do not undergo surgery following chemoradiation because of a clinical complete response?

What about for a patient with complete radiographic response who declines surgical management?

3 Answers available

Can CM577 regimen of adjuvant nivolumab s/p neoadjuvant chemoRT with residual disease following surgery be extrapolated to patients with R1 resection unable to undergo re-resection?

CheckMate 577 only included patients with R0 resection.For R1 resections, guidelines suggest observation vs re-resection only.

3 Answers available

Should we consider radiation therapy for patients with N2 EGFRm NSCLC who will receive osimertinib, though RT was excluded on ADAURA?

Conversely: In a patient with N2 EGFR+ NSCLC receiving radiation, would you still consider use of osimertinib?

4 Answers available

How do you manage patients on atezolizumab/bevacizumab with advanced HCC who develop arterial thrombosis?

Do you continue atezolizumab alone? Would you avoid anticoagulation?

6 Answers available

How do you decide between systemic vs. arterially directed therapies in the first line setting for unresectable HCC?

In light of the SIRveNIB trial results and now IMbrave150, what is the role of intra-arterial therapy now?

2 Answers available

Would you use upfront atezo/bev in a patient with HCC and untreated hepatitis?

3 Answers available

Papers discussed in this category

N Engl J Med, 2020 May 14

Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma.

Liver Cancer, 2019 Sep 18

A New Treatment Option for Intermediate-Stage Hepatocellular Carcinoma with High Tumor Burden: Initial Lenvatinib Therapy with Subsequent Selective TACE.

N Engl J Med, 2022 Sep 12

Neoadjuvant Cemiplimab for Stage II to IV Cutaneous Squamous-Cell Carcinoma.

Front Oncol, 2023 Jan 04

Case report: The power of immunotherapy in advanced cutaneous squamous cell carcinoma.

Br J Dermatol, 2015 Aug 08

Efficacy of neoadjuvant cetuximab alone or with platinum salt for the treatment of unresectable advanced nonmetastatic cutaneous squamous cell carcinomas.

Lancet, 1998 Jul 25

Postoperative radiotherapy in non-small-cell lung cancer: systematic review and meta-analysis of individual patient data from nine randomised controlled trials. PORT Meta-analysis Trialists Group.

Int. J. Radiat. Oncol. Biol. Phys., 2008-11-01

Impact of postoperative radiation therapy on survival in patients with complete resection and stage I, II, or IIIA non-small-cell lung cancer treated with adjuvant chemotherapy: the adjuvant Navelbine International Trialist Association (ANITA) Randomized Trial.

N Engl J Med, 2020 Sep 19

Osimertinib in Resected -Mutated Non-Small-Cell Lung Cancer.

N Engl J Med,

Adjuvant Nivolumab versus Placebo in Muscle-Invasive Urothelial Carcinoma.

Lancet Oncol, 2021 Mar 12

Adjuvant atezolizumab versus observation in muscle-invasive urothelial carcinoma (IMvigor010): a multicentre, open-label, randomised, phase 3 trial.

N Engl J Med, 2021-04-01

Adjuvant Nivolumab in Resected Esophageal or Gastroesophageal Junction Cancer.

Annals of surgery, 2009-05

Post-treatment endoscopic biopsy is a poor-predictor of pathologic response in patients undergoing chemoradiation therapy for esophageal cancer.

N. Engl. J. Med.,

Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer.

JAMA oncology, 2019-06-01

Gemcitabine, Cisplatin, and nab-Paclitaxel for the Treatment of Advanced Biliary Tract Cancers: A Phase 2 Clinical Trial.

Transpl Int, 2010 May 20

Liver transplantation for cholangiocarcinoma.

NEJM Evidence, 2022 Jun 1

Durvalumab plus Gemcitabine and Cisplatin in Advanced Biliary Tract Cancer

Eur J Surg Oncol,

Prevention of implantation metastases after resection of proximal bile duct tumours with pre-operative low dose radiation therapy.

World J Surg, 2019 Apr

Our Rationale of Initiating Neoadjuvant Chemotherapy for Hilar Cholangiocarcinoma: A Proposal of Criteria for "Borderline Resectable" in the Field of Surgery for Hilar Cholangiocarcinoma.

J Surg Oncol, 2020 Sep 24

Outcomes of neoadjuvant therapy for cholangiocarcinoma: A review of existing evidence assessing treatment response and R0 resection rate.

World J Gastrointest Surg, 2019 Jun 27

Neoadjuvant therapy in the treatment of hilar cholangiocarcinoma: Review of the literature.

J. Clin. Oncol., 2018 Mar 14

Postoperative Concurrent Chemoradiotherapy Versus Postoperative Radiotherapy in High-Risk Cutaneous Squamous Cell Carcinoma of the Head and Neck: The Randomized Phase III TROG 05.01 Trial.

Radiation Oncology

Journal Club ft. NEJM publications

Questions discussed in this category

Papers discussed in this category

Related Topics in Radiation Oncology